Glaucoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with primary open-angle glaucoma, confirmed by abnormal appearance of the optic nerve and abnormal visual field test results, with eye pressure of 21 mmHg or higher recorded on at least three occasions before treatment
- People diagnosed with normal tension glaucoma, confirmed by abnormal appearance of the optic nerve and abnormal visual field test results, with no recorded eye pressure above 20 mmHg before treatment
- People with ocular hypertension — meaning eye pressure of 21 mmHg or higher on at least three measurements, but with no signs of glaucoma damage to the optic nerve or visual field
- Healthy volunteers with normal eye exam results, eye pressure below 20 mmHg on at least three measurements, and no history of high eye pressure or glaucoma damage
- Within each glaucoma group, participants are divided based on the degree of visual field loss — either moderate-to-severe (loss of 10dB or more) or mild (less than 10dB loss) (confirm with trial site)
Who may not be able to join:
- People with a serious medical condition, as assessed by the trial investigator
- People who drink alcohol excessively
- People who smoke
- People who have taken part in another clinical trial within the past three weeks
- People with certain types of glaucoma, including exfoliation glaucoma, pigmentary glaucoma, or a history of acute angle closure
- People who have had eye surgery within the last six months
- People who have had an eye infection or inflammation within the last three months
- People with a history of epilepsy
- People with diabetes
- People with untreated high blood pressure above specific levels (systolic above 160 mmHg or diastolic above 95 mmHg)
- People who are pregnant
- People who are breastfeeding or planning to become pregnant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gerhard Garhöfer, MD, Department of Clinical Pharmacology, Medical University of Vienna
Phone: 004314040029810
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Flicker induced blood flow alterations
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.